Furthermore, the tumor tissue for molecular testing was limited with only a single CRC with sufficient DNA for WES and therefore, confirmation that HRD associated mutational signatures were the dominant mutational process in the other CRCs from BRCA1 carriers could not be determined. The gene discussed is BRCA1; the disease is colorectal carcinoma.